Guardant Health Valuation
| GH Stock | USD 101.87 0.13 0.13% |
At this time, the firm appears to be overvalued. Guardant Health retains a regular Real Value of $94.41 per share. The prevalent price of the firm is $101.87. Our model calculates the value of Guardant Health from evaluating the firm fundamentals such as return on asset of -0.2, and Return On Equity of -45.84 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Guardant Health's price fluctuation is very steady at this time. Calculation of the real value of Guardant Health is based on 3 months time horizon. Increasing Guardant Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Guardant Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Guardant Stock. However, Guardant Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 101.87 | Real 94.41 | Hype 100.65 | Naive 102.26 |
The intrinsic value of Guardant Health's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Guardant Health's stock price.
Estimating the potential upside or downside of Guardant Health helps investors to forecast how Guardant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Guardant Health more accurately as focusing exclusively on Guardant Health's fundamentals will not take into account other important factors: Guardant Health Total Value Analysis
Guardant Health is currently forecasted to have takeover value of 13.96 B with market capitalization of 13.21 B, debt of 1.34 B, and cash on hands of 853.69 M. Please note that takeover value may be misleading and is a subject to accounting mistakes. We encourage investors to methodically examine all of the Guardant Health fundamentals before making investment evaluation based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.96 B | 13.21 B | 1.34 B | 853.69 M |
Guardant Health Investor Information
About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.21. Guardant Health had not issued any dividends in recent years. Guardant Health is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Guardant Health Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Guardant Health has an asset utilization ratio of 49.74 percent. This signifies that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Guardant Health is more efficient with each dollar of assets it utilizes for everyday operations.Guardant Health Ownership Allocation
Guardant Health has a total of 129.87 Million outstanding shares. The majority of Guardant Health outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Guardant Health to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Guardant Health. Please pay attention to any change in the institutional holdings of Guardant Health as this could imply that something significant has changed or is about to change at the company. Also note that almost one million eight hundred fifty-seven thousand two hundred four invesors are currently shorting Guardant Health expressing very little confidence in its future performance.Guardant Health Profitability Analysis
The company generated the yearly revenue of 739.02 M. Annual Net Loss to common stockholders was (436.37 M) with gross profit of 575.46 M.About Guardant Health Valuation
An absolute valuation paradigm, as applied to Guardant Stock, attempts to find the value of Guardant Health based on its fundamental and basic technical indicators. By analyzing Guardant Health's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Guardant Health's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Guardant Health. We calculate exposure to Guardant Health's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Guardant Health's related companies.Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 1373 people.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |